2021

Pillar Biosciences received premarket approval from FDA for its ONCO/Reveal™ Dx Lung and Colon Cancer Assay Aug, 2021 Home  >  Resources  >  Press Release  > Pillar Biosciences received premarket approval from FDA for its ONCO/Reveal™ Dx Lung and Colon Cancer Assay Pillar Biosciences announced the U.S. Food and Drug Administration (FDA) has given Premarket Approval (PMA) to its ONCO/Reveal™ Dx Lung and Colon Cancer Assay, an NGS tissue-based companion diagnostic test for the qualitative detection of somatic mutations in DNA derived from non-small cell lung cancer (NSCLC) and colorectal (CRC) cancer tumors. Please click here for details.

Renovation of molecular diagnostic laboratory in HKSTP finished Jul, 2020 Home  >  Resources  >  Press Release  > Renovation of molecular diagnostic laboratory in HKSTP finished Joined Hong Kong Science and Technology (HKSTP) as a Tenant company and started to build a molecular diagnostic laboratory in HKSTP. AMDL started its centralized laboratory in the HKSTP, where it is a hub of talents and innovations in R&D industry in Hong Kong. We hope to encounter more opportunities with the world-class developers here.